Swiss National Bank Has $4.14 Million Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Swiss National Bank grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 220,000 shares of the biotechnology company’s stock after buying an additional 1,700 shares during the quarter. Swiss National Bank’s holdings in Arrowhead Pharmaceuticals were worth $4,136,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. World Investment Advisors LLC increased its position in Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 700 shares in the last quarter. Wellington Management Group LLP grew its holdings in Arrowhead Pharmaceuticals by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after acquiring an additional 886 shares during the period. Van ECK Associates Corp raised its position in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,250 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Arrowhead Pharmaceuticals by 5.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company’s stock valued at $586,000 after purchasing an additional 1,523 shares during the period. Finally, KBC Group NV boosted its position in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on ARWR shares. Piper Sandler dropped their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Sanford C. Bernstein reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Citigroup lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average price target of $41.44.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares of the company’s stock, valued at $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 289,167 shares of company stock valued at $5,106,735. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Trading Down 5.0 %

Shares of ARWR stock opened at $14.73 on Wednesday. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The company has a market cap of $2.02 billion, a PE ratio of -2.85 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $14.23 and a fifty-two week high of $30.41. The stock’s fifty day moving average price is $18.45 and its two-hundred day moving average price is $19.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.